Page 89 - Read Online

Pippione et al. Steroidogenic enzymes in prostate cancer

(AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)
flufenamic acid and indomethacin. Cancer Res 2004;64:1802-10. phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the
48. Flanagan JU, Yosaatmadja Y, Teague RM, Chai MZL, Turnbull AP, aldo-keto reductase enzyme AKR1C3. Eur J Med Chem 2013;62:738-
Squire CJ. Crystal structures of three classes of non-steroidal anti- 44.
inflammatory drugs in complex with aldo-keto reductase 1C3. PLoS 62. Jamieson SM, Brooke DG, Heinrich D, Atwell GJ, Silva S, Hamilton
One 2012;7:e43965. EJ, Turnbull AP, Rigoreau LJ, Trivier E, Soudy C, Samlal SS,
49. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, Owen PJ, Schroeder E, Raynham T, Flanagan JU, Denny WA.
Moore M, Palackal N, Ratnam K. Human 3alpha-hydroxysteroid 3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic acids: highly
dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto potent and selective inhibitors of the type 5 17-beta-hydroxysteroid
reductase superfamily: functional plasticity and tissue distribution dehydrogenase AKR1C3. J Med Chem 2012;55:7746-58.
reveals roles in the inactivation and formation of male and female sex 63. Yin YD, Fu M, Brooke DG, Heinrich DM, Denny WA, Jamieson SM.
hormones. Biochem J 2000;351:67-77. The activity of SN33638, an inhibitor of AKR1C3, on testosterone
50. Burczynski ME, Harvey RG, Penning TM. Expression and and 17beta-estradiol production and function in castration-resistant
characterization of four recombinant human dihydrodiol prostate cancer and ER-positive breast cancer. Front Oncol
dehydrogenase isoforms: oxidation of trans-7, 8-dihydroxy-7,8- 2014;4:159.
dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a] 64. Zhou W, Limonta P. AKR1C3 inhibition therapy in castration-resistant
pyrene-7,8-dione. Biochemistry 1998;37:6781-90. prostate cancer and breast cancer: lessons from responses to SN33638.
51. Byrns MC, Jin Y, Penning TM. Inhibitors of type 5 17beta- Front Oncol 2014;4:162.
hydroxysteroid dehydrogenase (AKR1C3): overview and structural 65. Flanagan JU, Atwell GJ, Heinrich DM, Brooke DG, Silva S, Rigoreau
insights. J Steroid Biochem Mol Biol 2011;125:95-104. LJ, Trivier E, Turnbull AP, Raynham T, Jamieson SM, Denny WA.
52. Adeniji AO, Chen M, Penning TM. AKR1C3 as a target in castrate Morpholylureas are a new class of potent and selective inhibitors of
resistant prostate cancer. J Steroid Biochem Mol Biol 2013;137:136- the type 5 17-beta-hydroxysteroid dehydrogenase (AKR1C3). Bioorg
49. Med Chem 2014;22:967-77.
53. Skarydova L, Hofman J, Chlebek J, Havrankova J, Kosanova K, 66. Kikuchi A, Furutani T, Azami H, Watanabe K, Niimi T, Kamiyama Y,
Skarka A, Hostalkova A, Plucha T, Cahlikova L, Wsol V. Isoquinoline Kuromitsu S, Baskin-Bey E, Heeringa M, Ouatas T, Enjo K. In vitro
alkaloids as a novel type of AKR1C3 inhibitors. J Steroid Biochem and in vivo characterisation of ASP9521: a novel, selective, orally
Mol Biol 2014;143:250-8. bioavailable inhibitor of 17beta-hydroxysteroid dehydrogenase type 5
54. Tian Y, Zhao L, Wang Y, Zhang H, Xu D, Zhao X, Li Y, Li J. (17betaHSD5; AKR1C3). Invest New Drugs 2014;32:860-70.
Berberine inhibits androgen synthesis by interaction with aldo- 67. Yepuru M, Wu Z, Kulkarni A, Yin F, Barrett CM, Kim J, Steiner MS,
keto reductase 1C3 in 22Rv1 prostate cancer cells. Asian J Androl Miller DD, Dalton JT, Narayanan R. Steroidogenic enzyme AKR1C3
2016;18:607-12. is a novel androgen receptor-selective coactivator that promotes
55. Akao Y, Maruyama H, Matsumoto K, Ohguchi K, Nishizawa K, prostate cancer growth. Clin Cancer Res 2013;19:5613-25.
Sakamoto T, Araki Y, Mishima S, Nozawa Y. Cell growth inhibitory 68. Loriot Y, Fizazi K, Jones RJ, Van den Brande J, Molife RL, Omlin
effect of cinnamic acid derivatives from propolis on human tumor cell A, James ND, Baskin-Bey E, Heeringa M, Baron B, Holtkamp GM,
Ouatas T, De Bono JS. Safety, tolerability and anti-tumour activity
lines. Biol Pharm Bull 2003;26:1057-9.
56. Endo S, Matsunaga T, Kanamori A, Otsuji Y, Nagai H, Sundaram of the androgen biosynthesis inhibitor ASP9521 in patients with
metastatic castration-resistant prostate cancer: multi-centre phase I/II
K, El-Kabbani O, Toyooka N, Ohta S, Hara A. Selective inhibition study. Invest New Drugs 2014;32:995-1004.
of human type-5 17beta-hydroxysteroid dehydrogenase (AKR1C3) 69. Enzalutamide and indomethacin in treating patients with recurrent or
by baccharin, a component of Brazilian propolis. J Nat Prod metastatic hormone-resistant prostate cancer. In: ClinicalTrials.gov;
2012;75:716-21. Identifier: NCT02935205. Available from: https://clinicaltrials.gov/
57. Ogihara T, Tamai I, Tsuji A. Structural characterization of substrates ct2/show/NCT02935205. [Last accessed on 13 Nov 2017]
for the anion exchange transporter in Caco-2 cells. J Pharm Sci 70. A phase II neoadjuvant study of ARN-509, abiraterone acetate,
1999;88:1217-21. prednisone, degarelix and indomethacin in men with localized prostate
58. Pippione AC, Dosio F, Ducime A, Federico A, Martina K, Sainas S, cancer pre-prostatectomy. Available from: http://www.centerwatch.
Frolund B, Gooyit M, Janda KD, Boschi D, Lolli ML. Substituted com/clinical-trials/listings/98162/stage-iii-prostate-adenocarcinoma-
4-hydroxy-1,2,3-triazoles: synthesis, characterization and first drug phase-ii-neoadjuvant-study/?&radius=50. [Last accessed on 13 Nov
design applications through bioisosteric modulation and scaffold 2017]
hopping approaches. Medchemcomm 2015;6:1285-92. 71. Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly
59. Sainas S, Pippione AC, Giorgis M, Lupino E, Goyal P, Ramondetti J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, Donate F,
C, Buccinna B, Piccinini M, Braga RC, Andrade CH, Andersson Wilson WR, Patterson AV. The bioreductive prodrug PR-104A is
M, Moritzer AC, Friemann R, Mensa S, Al-Kadaraghi S, Boschi activated under aerobic conditions by human aldo-keto reductase 1C3.
D, Lolli ML. Design, synthesis, biological evaluation and X-ray Cancer Res 2010;70:1573-84.
structural studies of potent human dihydroorotate dehydrogenase 72. Manesh DM, El-Hoss J, Evans K, Richmond J, Toscan CE, Bracken
inhibitors based on hydroxylated azole scaffolds. Eur J Med Chem LS, Hedrick A, Sutton R, Marshall GM, Wilson WR, Kurmasheva RT,
2017;129:287-302. Billups C, Houghton PJ, Smith MA, Carol H, Lock RB. AKR1C3 is
60. Pippione AC, Giraudo A, Bonanni D, Carnovale IM, Marini E, Cena a biomarker of sensitivity to PR-104 in preclinical models of T-cell
C, Costale A, Zonari D, Pors K, Sadiq M, Boschi D, Oliaro-Bosso S, acute lymphoblastic leukemia. Blood 2015;126:1193-202.
Lolli ML. Hydroxytriazole derivatives as potent and selective aldo- 73. Marchais-Oberwinkler S, Henn C, Moller G, Klein T, Negri M, Oster
keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric A, Spadaro A, Werth R, Wetzel M, Xu K, Frotscher M, Hartmann RW,
scaffold hopping approach. Eur J Med Chem 2017;139:936-46. Adamski J. 17beta-Hydroxysteroid dehydrogenases (17beta-HSDs) as
61. Heinrich DM, Flanagan JU, Jamieson SM, Silva S, Rigoreau LJ, therapeutic targets: protein structures, functions, and recent progress
Trivier E, Raynham T, Turnbull AP, Denny WA. Synthesis and in inhibitor development. J Steroid Biochem Mol Biol 2011;125:66-

Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ December 12, 2017 357